Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18884161 | 1.00 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL18878031 | 1.00 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL18884046 | 1.00 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL14410771 | 0.97 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL14410779 | 0.94 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL846707 | 0.91 | — | — | |
| SCHEMBL13676327 | 0.91 | — | — | |
| SCHEMBL10256885 | 0.86 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL19797925 | 0.83 | MEN1 (0.31) | — | |
| SCHEMBL14410769 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240209004-A1 | BORIC ACID DERIVATIVE ACTING AS Beta-LACTAMASE INHIBITOR | TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240209004-A1 | BORIC ACID DERIVATIVE ACTING AS Beta-LACTAMASE INHIBITOR | TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7622468-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7618971-B2 | Mitotic kinesin inhibitors | MERCK & CO. INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7524862-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-28 | — | — | US | disclosed |
| US-7524862-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-28 | — | — | US | disclosed |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080027058-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | MAPK1 3803/4885 |
| US-20240209004-A1 | BORIC ACID DERIVATIVE ACTING AS Beta-LACTAMASE INHIBITOR | TREH, ME1, BCAT2 | MAPK1 623/4885 |
| US-20080027058-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF23 | MAPK1 1299/4885 |
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WEE1, CYP51A1, WEE2 | MAPK1 655/4885 |
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | MAPK1 4357/4885 |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | MAPK1 2442/4885 |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | MAPK1 2194/4885 |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | MAPK1 1443/4885 |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | MAPK1 1573/4885 |
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | KRAS, NRAS, HRAS | MAPK1 139/4885 |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1A, TET1, KDM3A | MAPK1 2269/4885 |
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HCRTR1, HCRTR2, CCKBR | MAPK1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.